Breaking News

Scorpius BioManufacturing to Support Phase 2 Clinical Program

To provide process development, analytical, and cGMP manufacturing services.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NightHawk Biosciences, a CDMO, announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a publicly traded biotech company’s Phase 2 clinical program.   Jeff Wolf, CEO of NightHawk Biosciences, said, “We are proud to have been selected to help advance this potentially lifesaving therapy through the clinic. Scorpius has multiple clients with Orphan Drug Designations from ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters